Cetera Trust Company N.A Makes New Investment in Boston Scientific Co. (NYSE:BSX)

Cetera Trust Company N.A bought a new position in shares of Boston Scientific Co. (NYSE:BSX) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 746 shares of the medical equipment provider’s stock, valued at approximately $43,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in BSX. FMR LLC raised its position in shares of Boston Scientific by 6.8% in the 3rd quarter. FMR LLC now owns 125,920,357 shares of the medical equipment provider’s stock valued at $6,648,595,000 after purchasing an additional 8,045,263 shares during the last quarter. American Century Companies Inc. raised its position in shares of Boston Scientific by 391.6% in the 3rd quarter. American Century Companies Inc. now owns 3,271,810 shares of the medical equipment provider’s stock valued at $172,752,000 after purchasing an additional 2,606,253 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Boston Scientific by 5.9% in the 3rd quarter. Wellington Management Group LLP now owns 42,076,529 shares of the medical equipment provider’s stock valued at $2,221,641,000 after purchasing an additional 2,336,348 shares during the last quarter. Winslow Capital Management LLC raised its position in shares of Boston Scientific by 39.3% in the 3rd quarter. Winslow Capital Management LLC now owns 6,129,573 shares of the medical equipment provider’s stock valued at $323,641,000 after purchasing an additional 1,730,133 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Boston Scientific by 1.2% in the 3rd quarter. Vanguard Group Inc. now owns 123,768,348 shares of the medical equipment provider’s stock valued at $6,534,969,000 after purchasing an additional 1,525,432 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $66.89, for a total value of $467,092.87. Following the completion of the transaction, the executive vice president now directly owns 56,508 shares of the company’s stock, valued at approximately $3,779,820.12. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $66.89, for a total value of $467,092.87. Following the completion of the transaction, the executive vice president now directly owns 56,508 shares of the company’s stock, valued at approximately $3,779,820.12. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Edward J. Ludwig sold 7,000 shares of Boston Scientific stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $65.03, for a total value of $455,210.00. Following the completion of the transaction, the director now directly owns 41,374 shares of the company’s stock, valued at $2,690,551.22. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 50,979 shares of company stock worth $3,418,529. Company insiders own 0.50% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on BSX. Royal Bank of Canada increased their price objective on shares of Boston Scientific from $70.00 to $78.00 and gave the company an “outperform” rating in a research report on Monday, April 15th. JPMorgan Chase & Co. raised their price objective on shares of Boston Scientific from $60.00 to $72.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. BTIG Research reissued a “buy” rating and issued a $64.00 price target on shares of Boston Scientific in a research note on Friday, December 29th. TD Cowen lifted their price target on shares of Boston Scientific from $65.00 to $77.00 and gave the company an “outperform” rating in a research note on Thursday, March 7th. Finally, Raymond James lifted their price target on shares of Boston Scientific from $67.00 to $73.00 and gave the company a “strong-buy” rating in a research note on Thursday, February 1st. Two equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $68.50.

Boston Scientific Stock Up 1.0 %

Shares of BSX opened at $68.02 on Tuesday. The firm has a market cap of $99.79 billion, a P/E ratio of 63.57, a price-to-earnings-growth ratio of 2.36 and a beta of 0.78. Boston Scientific Co. has a 12-month low of $48.35 and a 12-month high of $69.21. The company’s 50-day moving average price is $67.31 and its 200 day moving average price is $60.07. The company has a current ratio of 1.32, a quick ratio of 0.82 and a debt-to-equity ratio of 0.44.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, January 31st. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.51 by $0.04. The firm had revenue of $3.73 billion for the quarter, compared to analyst estimates of $3.59 billion. Boston Scientific had a net margin of 11.19% and a return on equity of 15.99%. During the same period in the previous year, the firm earned $0.45 EPS. On average, sell-side analysts forecast that Boston Scientific Co. will post 2.25 earnings per share for the current year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.